A daily pill to fight breast cancer? Swiss firm’s new drug completes 3 phases of human trials
Article excerpt
Highlighted: the sentence this signal was extracted from
Depth, context and analysis New Delhi: Swiss healthcare company F Hoffmann-La Roche AG is seeking US approval for a new breast cancer pill, giredestrant, which it expects could generate up to $15 billion in revenue, according to a Bloomberg report . The drug has completed three phases of human trials, and the US Food and Drug Administration (FDA) is expected to decide on its approval by late November or early December. Giredestrant is a once-daily pill designed to block and degrade estrogen receptors, which can fuel the growth of certain breast cancers. The FDA has granted the drug priority review, expediting the approval process. Results from a global Phase III trial of the drug were published in the New England Journal of Medicine on 1 October. The study included 373 women and men with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease had progressed or returned after treatment. The findings showed that patients who took giredestrant after surgery had a lower risk of cancer recurrence than those who received standard hormone therapy. The drug was also better tolerated, with fewer patients discontinuing treatment because of adverse effects. Giredestrant is designed to target breast cancer tumours that are hormone receptor-positive, meaning their growth is driven by hormones such as estrogen. It belongs to a class of drugs known as selective...
Keep reading with a free account
The rest of this article, and every signal for Roche, is in your free account.
